Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review
Open Access
- 14 December 2018
- journal article
- review article
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 16 (1) , 79
Abstract
Tocilizumab, an anti-interleukin-6 (IL-6) agent, is indicated as a treatment for several autoimmune or inflammatory diseases, including rheumatoid arthritis and juvenile idiopathic arthritis (JIA). IL-6 plays roles in both immune system dysregulation and inflammation, and thus efforts to extend the utility of tocilizumab in patients with autoinflammatory conditions are ongoing. Here, we survey the literature on the off-label use of tocilizumab in patients with juvenile-onset rheumatic diseases including juvenile systemic lupus erythematosus (SLE), juvenile dermatomyositis (DM), vasculitis, juvenile scleroderma, and other autoinflammatory diseases. There is no real evidence that tocilizumab is useful for patients with SLE and juvenile DM, but several cases of childhood Takayasu arteritis have experienced promising outcomes. In juvenile-onset scleroderma, for which no therapy that can halt disease progression is available, tocilizumab may stop progression and the associated functional impairment. Tocilizumab prevents systemic inflammation in patients with Kawasaki’s disease, but may develop coronary aneurysms. Tocilizumab has been used to treat several pediatric autoinflammatory diseases, including JIA-associated uveitis and Castleman’s disease. Further work in larger populations is necessary to confirm the effects of tocilizumab in patients with pediatric rheumatic diseases.Keywords
This publication has 86 references indexed in Scilit:
- Sustained remission of severe multicentric castleman disease following multiagent chemotherapy and tocilizumab maintenancePediatric Blood & Cancer, 2013
- Efficacy of tocilizumab for interstitial lung disease in an undifferentiated autoinflammatory disorder partially responsive to anakinraRheumatology, 2013
- Successful Tocilizumab Treatment in a Child With Refractory Takayasu ArteritisPediatrics, 2012
- Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidenceClinical Rheumatology, 2012
- Successful Use of Interleukin 6 Antagonist Tocilizumab in a Patient With Refractory Cutaneous Lupus and Urticarial VasculitisJCR: Journal of Clinical Rheumatology, 2012
- Tocilizumab in refractory adult Still's diseaseArthritis Care & Research, 2010
- Prevalence and burden of pediatric-onset systemic lupus erythematosusNature Reviews Rheumatology, 2010
- Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open‐label phase I dosage‐escalation studyArthritis & Rheumatism, 2010
- TocilizumabDrugs, 2009
- Molecular cloning and expression of an IL-6 signal transducer, gp130Cell, 1990